Neutralizing antibodies in oral immunotherapy
Peanut oral immunotherapy, which involves the consistent ingestion of increasing amounts of peanut allergen as a form of desensitization, induced long-term responses in only a small subset of treated individuals. We sought to understand the molecular determinants underlying this induction of sustained tolerance to peanut. Our work has led to the identification of neutralizing antibodies and their role in sustained responses after therapy. These antibodies effectively bind to allergen and block allergic reactions due to their unique structural features. We aim to more fully understand why some individuals are more likely to develop these antibodies than others, and why immunotherapy is more successful at a young age.